Agile Sciences Receives $1.5M Phase II STTR Grant

RALEIGH, N.C. - July 14, 2014 - PRLog -- The National Institutes of Health (NIH) has awarded Agile Sciences a $1.5 million Phase II STTR Grant to support pre-clinical development of Agile Sciences’ proprietary Agilyte^® anti-biofilm molecules for treating lung infections of cystic fibrosis patients. The project will build upon promising data that was generated as a result of the previous NIH Phase I grant award. The Phase II project will be led by Principal Investigator Dr. Angela Pollard, and will include collaboration with Dr. Richard Boucher, Kenan Professor of Medicine and Director of the Cystic Fibrosis Center at UNC Chapel Hill, and Dr. Matthew Wolfgang, Associate Professor at the UNC Chapel Hill School of Medicine.

Dr. Eva Garland, Agile Sciences’ Vice President of Research and Development, stated, “This award speaks to the success of the Phase I studies and the potential of Agile Sciences’ technology to provide a therapeutic advantage in the treatment of lung infections in cystic fibrosis patients.”

“We are grateful to be collaborating with Dr. Boucher and Dr. Wolfgang, who are leaders in cystic fibrosis research.  Their expertise will be instrumental in continuing to advance pre-clinical development of Agile Sciences’ therapeutic for cystic fibrosis,” noted Dr. Pollard.

Dr. Boucher commented, “I am pleased to participate in Agile Sciences’ NIH project. The company’s technology has the potential to address lung infections that plague cystic fibrosis patients, resulting in extensive medical treatments and hospital stays.”

This NIH STTR project will begin immediately and continue through June 30, 2016.